Results 261 to 270 of about 47,852 (311)

[Oral hormone contraception].

Acta medica portuguesa, 2001
The authors focus on the main goals of hormonal contraception with special attention to its benefits regarding some pathological situations. Post coital, post partum and adolescent hormonal contraception are reviewed in detail. The authors also point out the contraindications to its prescription.
openaire   +1 more source

Oral contraceptives, hormone therapy and cardiovascular risk

Climacteric, 2008
Soon after combined estrogen/progestogen oral contraceptives (COCs) were introduced in the 1950s, it was established that they cause venous thromboembolism (VTE), that the risk is related to estrogen dose, and that COCs also increase the risk of myocardial infarction among female smokers over age 35. Stroke risk is also increased.
openaire   +2 more sources

FIBROCYSTIC DISEASE IN WOMEN RECEIVING ORAL CONTRACEPTIVE HORMONES

Obstetrical & Gynecological Survey, 1970
To assess the effect of oral contraceptive hormones on breast tissue in women with fibrocystic disease a group of 25 women who had been using oral contraceptives and had developed this disease were compared with a group of 25 women who had fibrocystic disease but had never used oral contraceptives. No single oral contraceptive preparation was studied.
openaire   +2 more sources

The Future of Oral Hormonal Contraception

1999
Each second, the world population increases by three newborn babies (98 million per year); nine out of ten are born in developing countries. In 2050, the total population will be 12.5 billion instead of the 6 billion of today. No war, no disease, but only access to and the acceptance of effective methods of fertility control can stop the growth of the ...
Thomas Rabe, Benno Runnebaum
openaire   +1 more source

[New progestins in oral hormonal contraceptives].

Archives of gynecology and obstetrics, 1989
Three new progestins with a high gestagenic potency have been developed as derivatives of the levonorgestrel (in brackets: biological active substance in the human): desogestrel (3-keto-desogestrel), norgestimate (norgestimate), gestodene (gestodene). In combination with low dosages of ethinylestradiol (30-35 micrograms) an excessive steroid overload ...
B, Runnebaum, T, Rabe
openaire   +1 more source

Oral hormonal contraception in special circumstances.

Australian family physician, 2018
Despite the general consensus that long-acting reversible contraceptives (LARCs) are the most appropriate choice of contraception for most women, there are special circumstances when the contraceptive and non-contraceptive needs of the patient are met by oral methods.By using case histories, we seek to demonstrate the medical and practical complexities
Patricia, Moore, Catherine, Streeton
openaire   +1 more source

[Current oral hormonal contraception ].

Akusherstvo i ginekologiia, 2009
  +7 more sources

Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials

Lancet, The, 2022
Jacques Donnez, Felice Petraglia, Ayman Al-Hendy   +2 more
exaly  

ORAL CONTRACEPTIVES AND LUTEINISING HORMONE

The Lancet, 1966
GriffT. Ross, WilliamD. Odell, PhillipL. Rayford   +2 more
openaire   +1 more source

The Current State of Hormonal Therapy for Prostate Cancer

Ca-A Cancer Journal for Clinicians, 2002
Kenneth J Pienta, Brent K Hollenbeck
exaly